Over the course of a 3‐week treatment, we observed that, compared with monotherapy, the combination of sorafenib and MK2 Inhibitor III elicited a more pronounced inhibition of the tumor burden (Figure 7H–M). Here, MAPKAPK2 is linked to neoplasm.